A5069036413- Sarcoma Diagnosis and Treatment
- RNA Interference and Gene Delivery
- Immunotherapy and Immune Responses
- Virus-based gene therapy research
- Angiogenesis and VEGF in Cancer
- Cancer Cells and Metastasis
- Immune Cell Function and Interaction
- CAR-T cell therapy research
- Cytokine Signaling Pathways and Interactions
- Chemotherapy-induced cardiotoxicity and mitigation
- Immune cells in cancer
- RNA modifications and cancer
- Cancer, Hypoxia, and Metabolism
- Cell death mechanisms and regulation
- Cancer Immunotherapy and Biomarkers
- Cell Adhesion Molecules Research
- Peptidase Inhibition and Analysis
- Cancer Research and Treatments
- MicroRNA in disease regulation
- Immune Response and Inflammation
- Nanoparticle-Based Drug Delivery
- Histone Deacetylase Inhibitors Research
- Chemokine receptors and signaling
- Cancer therapeutics and mechanisms
- Cancer Genomics and Diagnostics
The University of Texas MD Anderson Cancer Center
2015-2024
University of Houston
2008-2021
The University of Texas Health Science Center at Houston
2020
Data Harbor (United States)
2015
Emory University
2014
Society of Surgical Oncology
2014
The University of Texas at Austin
2013
Yale University
2010
Seattle Children's Hospital
2005-2010
Children's Oncology Group
2005-2010
To compare three-drug chemotherapy with cisplatin, doxorubicin, and methotrexate four-drug methotrexate, ifosfamide for the treatment of osteosarcoma. determine whether addition muramyl tripeptide (MTP) to enhances event-free survival (EFS) overall in newly diagnosed patients osteosarcoma.Six hundred sixty-two osteosarcoma without clinically detectable metastatic disease whose was considered resectable received one four prospectively randomized treatments. All identical cumulative doses...
To determine whether the addition of ifosfamide and/or muramyl tripeptide (MTP) encapsulated in liposomes to cisplatin, doxorubicin, and high-dose methotrexate (HDMTX) could improve probability for event-free survival (EFS) newly diagnosed patients with osteosarcoma (OS).Six hundred seventy-seven OS without clinically detectable metastatic disease were treated one four prospectively randomized treatments. All received identical cumulative doses HDMTX underwent definitive surgical resection...
The addition of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) to chemotherapy has been shown improve overall survival in patients with nonmetastatic osteosarcoma (OS). authors report the results MTP-PE for metastatic OS.Intergroup-0133 was a prospective randomized phase 3 trial treatment newly diagnosed OS. compared 3-drug cisplatin, doxorubicin, and high-dose methotrexate (Regimen A) same drugs ifosfamide B). evaluated.Five-year event-free (EFS) who received (n = 46) 42%...
Abstract The ability of osteosarcoma cells to form lung metastases has been inversely correlated cell surface Fas expression. Downregulation allows circumvent FasL-mediated apoptosis upon entrance into the FasL+ microenvironment. However, mechanism regulation remains unclear. Here, we show that miRNA plays a role in downregulation expression osteosarcoma. Expression levels several members miR-17–92 cluster including miR-20a and miR-19a were found be higher metastatic low-Fas–expressing LM7...
Abstract To date, no specific marker exists for the detection of circulating tumor cells (CTC) from different types sarcomas, though tools are available CTCs in peripheral blood patients with cancer epithelial cancers. Here, we report cell-surface vimentin (CSV) as an exclusive on sarcoma CTC regardless tissue origin detected by a novel monoclonal antibody. Utilizing CSV probe, isolated and enumerated high sensitivity specificity bearing sarcoma, validating their phenotype single cell...
Abstract Osteosarcoma (OS) pulmonary metastasis translates into poor patient survival. The implication of PD‐1‐PD‐L1 pathway in the context NK cells and/or macrophages OS is unknown. We investigated effect anti‐PD‐1 lung and role responses. A human LM7 mouse model was used. Immunohistochemistry for tissues (PD‐L1, caspase‐3, Ki‐67, cells, macrophages), Western blotting tumors (p‐Stat3, p‐Erk1/2) performed. were assessed using flow cytometry. cell macrophage depletion conducted anti‐asialo...
Abstract Despite successful primary tumor treatment, the development of pulmonary metastasis continues to be most common cause mortality in patients with osteosarcoma. A conventional drug path requiring drugs induce regression established lesions has not led improvements for osteosarcoma more than 30 years. On basis our growing understanding biology, it is now reasonable and essential that we focus on developing therapeutics target metastatic progression. To advance this agenda, a meeting...
Osteosarcoma metastasizes to the lung, and there is a link between predominance of tumor-promoting immunosuppressive M2 macrophages in metastases poor patient survival. By contrast, M1 macrophage correlates with longer can be induced by various stimuli tumor microenvironment, including exosomes, which are 40- 150-nm vesicles that involved intercellular communication contribute progression immune evasion. Recognizing cells influence microenvironment make it more permissive because dominance...
Type 1 conventional dendritic cells (cDC1s) possess efficient antigen presentation and cross-presentation activity, as well potent T cell priming ability. Tissue-resident cDC1s (CD103+ in mice, CD141+ humans) are linked with improved tumor control, yet the efficacy of immunotherapy using this population is understudied.We generated murine CD103+ vitro examined their expression cDC1-related factors, accumulation tumor-draining lymph nodes (TdLNs). The antitumor vitro-generated was studied...
Human peripheral blood monocytes from normal donors obtained by separation on a Percoll gradient showed considerable cytotoxicity against tumor cells when preincubated in vitro for 24 hr with human monocyte-derived interleukin 1 (IL 1). In contrast, after pretreatment medium alone had low cytotoxic activity. All the IL preparations, including which was purified high-performance liquid column chromatography (HPLC), as well crude culture supernatant promoted monocyte-mediated same...
Human peripheral blood mononuclear cells from normal donors obtained by separation on a Percoll gradient were incubated with free or liposome-entrapped lymphokines produced concanavalin A-stimulated lymphocytes and then tested for cytotoxic activity against tumor cells. The treated monocytes lysed tumorigenic melanoma glioblastoma target cells, but had no effect three types of nontumorigenic activation to become tumoricidal was caused macrophage-activating factor (MAF) not contamination...
The treatment of osteosarcoma pulmonary metastases remains a challenge. T cells genetically modified to express chimeric antigen receptor (CAR), which recognizes tumor-associated antigen, have shown activity against hematopoietic malignancies in clinical trials, but this requires the identification specific on tumor cell. In current study, we found that interleukin (IL)-11Rα was selectively expressed 14 16 patients' lung and four different human cell lines, indicating IL-11Rα may be novel...
Abstract Metastasis continues to be the leading cause of mortality for patients with cancer. Several years ago, it became clear that chemokines and their receptors could control tumor progress. CXCR3 has now been identified in many cancers including osteosarcoma ligands were expressed by lungs are primary sites which this metastasize. This study tested hypothesis disruption CXCR3/CXCR3 complexes lead a decrease metastasis. The experimental design involved use antagonist, AMG487 2 murine...
Abstract Angiogenesis plays an essential role in tumor growth and metastasis is a promising therapeutic target for cancer. Vascular endothelial factor (VEGF) key regulator vasculogenesis as well angiogenesis. TC71 human Ewing's sarcoma cells overexpress VEGF, with shift isoform production from membrane-bound VEGF189 to the more soluble VEGF165. Transfection of vector-based VEGF targeted small interfering RNA expression system (VEGFsi) inhibited VEGF165 by 80% protein 98%, no alteration...
Muramyl tripeptide phosphatidylethanolamine (MTP-PE) is a synthesized lipophilic analogue of muramyl dipeptide. MTP-PE encapsulated in liposomes (L-MTP-PE) allows selective delivery to pulmonary macrophages and circulating monocytes. In vivo administration has resulted tumor regression mice with B16 melanoma lung lymph node metastases 40% long-term disease-free survival dogs osteosarcoma. Phase I studies have demonstrated that the drug well tolerated. A II trial using L-MTP-PE was undertaken...